iShares MSCI All Country Asia ex Jpn ETF (AAXJ) Reaches $76.80 Formed H&S; Oracle Investment Management Upped By $568,361 Its Epizyme (EPZM) Holding

Epizyme, Inc. (NASDAQ:EPZM) Logo

iShares MSCI All Country Asia ex Jpn ETF (AAXJ) formed H&S with $72.96 target or 5.00% below today’s $76.80 share price. iShares MSCI All Country Asia ex Jpn ETF (AAXJ) has $4.76B valuation. The ETF decreased 0.86% or $0.67 during the last trading session, reaching $76.8. About 478,009 shares traded. iShares MSCI All Country Asia ex Jpn ETF (NASDAQ:AAXJ) has risen 14.59% since June 14, 2017 and is uptrending. It has outperformed by 2.02% the S&P500.

Oracle Investment Management Inc increased Epizyme Inc (EPZM) stake by 9.21% reported in 2018Q1 SEC filing. Oracle Investment Management Inc acquired 33,433 shares as Epizyme Inc (EPZM)’s stock rose 3.36%. The Oracle Investment Management Inc holds 396,325 shares with $7.04 million value, up from 362,892 last quarter. Epizyme Inc now has $1.09 billion valuation. The stock decreased 2.18% or $0.35 during the last trading session, reaching $15.7. About 162,740 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has risen 14.24% since June 14, 2017 and is uptrending. It has outperformed by 1.67% the S&P500. Some Historical EPZM News: ; 23/04/2018 – FDA orders a partial hold on Epizyme’s lead cancer drug tazemetostat following T-cell lymphoma case $EPZM; 23/04/2018 – FDA Issues Partial Clinical Hold on Epizyme’s Lead Cancer Drug Tazemetostat — Market Mover; 13/03/2018 – EPIZYME 4Q LOSS/SHR 52C, EST. LOSS/SHR 57C; 24/05/2018 – Epizyme Granted FDA Orphan Drug Status for Tazemetostat; 08/05/2018 – EPIZYME 1Q LOSS/SHR 49C, EST. LOSS/SHR 54C; 23/04/2018 – EPIZYME INC EPZM.O – EPIZYME HAS BEGUN DEVELOPING MODIFICATIONS TO ADDRESS PARTIAL CLINICAL HOLD; 17/05/2018 – Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress; 17/05/2018 – #ASCO18 $EPZM another very underwhelming dataset 3% (2/61) ORR rather laughable in a biomarker enriched population Oh btw the drug also on clinical hold for causing secondary cancer; 20/04/2018 – DJ Epizyme Inc, Inst Holders, 1Q 2018 (EPZM); 23/04/2018 – EPIZYME INC EPZM.O – CO WILL NEED TO CONFIRM ALIGNMENT WITH FDA IN ORDER TO RESUME U.S. ENROLLMENT

Since February 5, 2018, it had 0 buys, and 1 sale for $1.20 million activity. Ros Matthew sold $1.20 million worth of stock.

Investors sentiment increased to 1.5 in 2018 Q1. Its up 0.29, from 1.21 in 2017Q4. It improved, as 13 investors sold EPZM shares while 25 reduced holdings. 22 funds opened positions while 35 raised stakes. 57.44 million shares or 0.90% more from 56.93 million shares in 2017Q4 were reported. Jpmorgan Chase has 195,412 shares. California Employees Retirement reported 135,500 shares. Great West Life Assurance Company Can invested in 0% or 4,800 shares. 988 were reported by Zurcher Kantonalbank (Zurich Cantonalbank). Fmr Limited Liability reported 7.43M shares or 0.02% of all its holdings. Point72 Asia (Hong Kong) Ltd holds 0.02% or 1,899 shares in its portfolio. Weiss Multi has invested 0.01% in Epizyme, Inc. (NASDAQ:EPZM). 72,826 were accumulated by Sio Mngmt Ltd Liability. State Street holds 0% or 1.80 million shares. Bailard holds 0.03% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 25,000 shares. Fred Alger Mgmt Incorporated stated it has 20,000 shares or 0% of all its holdings. Schwab Charles Invest Incorporated accumulated 264,011 shares or 0% of the stock. 10,088 were accumulated by Bnp Paribas Arbitrage Sa. California State Teachers Retirement owns 0% invested in Epizyme, Inc. (NASDAQ:EPZM) for 74,464 shares. Tekla Management Limited Liability Co invested in 485,325 shares or 0.34% of the stock.

Among 13 analysts covering Epizyme (NASDAQ:EPZM), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Epizyme had 37 analyst reports since August 6, 2015 according to SRatingsIntel. On Wednesday, March 14 the stock rating was maintained by H.C. Wainwright with “Buy”. The company was maintained on Wednesday, June 14 by Oppenheimer. The rating was maintained by Leerink Swann with “Buy” on Tuesday, April 24. On Thursday, August 6 the stock rating was maintained by Mizuho with “Buy”. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. The company was maintained on Monday, June 5 by Oppenheimer. As per Tuesday, August 1, the company rating was maintained by Oppenheimer. Leerink Swann maintained it with “Buy” rating and $22.0 target in Thursday, November 2 report. The firm has “Buy” rating by Zacks given on Tuesday, August 25. The company was maintained on Wednesday, March 14 by Leerink Swann.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart